Galectin Therapeutics Cash Flow - Annual (NASDAQ:GALT)

Add to My Stocks
$5.74 $0.32 (5.9%) GALT stock closing price Sep 17, 2018 (Closing)

The Galectin Therapeutics cash flow statement is one of the three reports that the company generates every quarter. Financials statements like the Galectin Therapeutics income statement and Galectin Therapeutics balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. This statement can tell if a company is running out of money while still being profitable and is useful in Galectin Therapeutics stock analysis. Galectin Therapeutics had a negative net income cash flow of $-16.23M for the latest 2017. This report is very useful in measuring the short term viability of a company. Galectin Therapeutics has a negative cash and cash equivalents change of $-12.3M.

View details of Galectin Therapeutics cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-0.8M2.54M-0.36M-1.11M--0.62M1.46M-1.77M-2.26M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.14M2.47M3.4M4.47M3.78M2.79M3.76M1.95M1.76M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment------0.01M-0.01M---
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----0.4M------
Other Cash Inflow (Outflow) from Investment Activities-------0.01M---
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares3.58M5.92M13.7M31.46M8.6M10.4M6.19M8.74M4.02M3.45M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities---------0.2M-
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year15.36M25.84M29.12M10.48M9.36M6.39M5.89M--1.31M
Cash & Equivalents at Year End3.05M15.36M25.84M29.12M10.48M9.36M6.39M5.89M--
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Galectin Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Galectin Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:

  • Galectin Therapeutics saw a negative change in Net Change in Cash and Cash Equivalents of $-12.3M in 2017. Apart from the Galectin Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Galectin Therapeutics lost $-15.89M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $- for GALT in last 2017 report.
  • Cash flow from financing activities shows the flow of cash between Galectin Therapeutics and its owners and creditors and was $3.58M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Galectin Therapeutics Cash Flow